跳至主要内容
临床试验/NCT05827432
NCT05827432暂停不适用

Field-Cycling Imaging Effectiveness in Non-alcoholic Fatty Liver Disease Stratification

NHS Grampian2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年3月最近更新:
适应症

试验速览

阶段
不适用
状态
暂停
发起方
NHS Grampian
入组人数
10
试验地点
2
主要终点
Differentiation of NAFLD types, from steatosis to liver fibrosis, assessed by Field-Cycling Imaging (FCI) scan

研究概览

简要总结

The goal of this pilot study is exploring whether field-cycling imaging may be able to detect characteristics of liver disease in patients with different degree of non-alcoholic fatty liver disease (NAFLD) that could be important in reflecting disease progression.

详细描述

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of diseases extending from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Currently, there is a pressing unmet clinical need to develop an effective non-invasive method to differentiate between different types of NAFLD and to support the initiation and monitoring of treatments designed to slow or halt progression of the disease.

Field-cycling imaging (FCI) is an innovative imaging technology pioneered at the University of Aberdeen. It has the ability to image human tissues non-invasively over a wide range of magnetic field strengths, directly informing on multi-scale tissue structure from nanometres to micrometres. This is not possible with traditional MRI. The potential of FCI in imaging NAFLD is particularly promising, due to its high sensitivity in quantifying and distinguishing protein content from fat.

The purpose of this pilot study is exploring whether FCI may be able to detect characteristics of liver disease, in patients with different degree of steatohepatitis and NAFLD, that could be important in reflecting progression of steatosis to liver fibrosis and HCC thereby potentially offering new diagnostic information that cannot be readily obtained with currently available imaging techniques.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants with a diagnosis of NAFLD
  • Participants must be aged 18 and above
  • Participants who meet the safety criteria for undergoing an MRI scan
  • Participants who are able to fit inside the scanner
  • Participants must be able to give fully informed consent
  • Participants must be mobile enough to be positioned onto the FCI scanner couch

排除标准

  • MRI-incompatible conditions, as detected in the MRI safety screening sheet
  • Participants under 18 years old
  • Participants who are unable to communicate in English
  • Participants who are unable to give fully informed consent
  • Women who are pregnant
  • Restrictions to mobility that would prevent the correct positioning in the scanner
  • Participants who suffer from claustrophobia

结局指标

主要结局

Differentiation of NAFLD types, from steatosis to liver fibrosis, assessed by Field-Cycling Imaging (FCI) scan

时间窗: At baseline

Validation of FCI T1 dispersion profiles as a non-invasive technology to map out structural information on NAFLD that is not available by standard methods, by distinguishing protein content from fat, with application for medical research.

次要结局

  • NAFLD progression assessed by Field-Cycling Imaging (FCI) T1 dispersion profiles of liver tissue(At baseline)

研究者

发起方
NHS Grampian
申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验